Chronic central serous chorioretinopathy complicated with CNV
Conditions
Interventions
good effects group:anti-VEGF drugs
bad effects group:anti-VEGF drugs
Sponsors
Eye and ENT hospital of Fudan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Willing to participate in this study and sign an informed consent form; (2) Chronic CSC with CNV diagnosed by FFA, ICG and OCTA; vision loss and persistent SRF >=6 months.
Exclusion criteria
Exclusion criteria: (1) Patients who have previously received any anti-VEGF treatment or PDT treatment; (2) Spherical equivalent> 2D; amblyopia; anisometropia; or history of other eye diseases, surgery and trauma, etc.; (3) History of intravenous fluorescein and indigo allergy; (4) Patients with poorly controlled hypertension and diabetes, patients with renal insufficiency other than cardiovascular and cerebrovascular diseases in the last 3 months; (5) Being participating in or have participated in other relevant clinical trial treatments within the last 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| best corrected visual acuity;central macular thickness; | — |
Secondary
| Measure | Time frame |
|---|---|
| the characteristics of CNV;the characteristics of choriodal vascular; | — |
Countries
China
Contacts
Public ContactGuo Jingli
Eye and ENT hospital of Fudan University
Outcome results
None listed